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The aim of the present research work was to investigate the enzyme inhibitory potential of some new 
sulfonamides having benzodioxane and acetamide moieties. The synthesis was started by the reaction of 
N-2,3-dihydrobenzo[1,4]-dioxin-6-amine (1) with 4-methylbenzenesulfonyl chloride (2) in the presence of 
10% aqueous Na2CO3 to yield N-(2,3-dihydrobenzo[1,4]-dioxin-6-yl)-4-methylbenzenesulfonamide (3), 
which was then reacted with 2-bromo-N-(un/substituted-phenyl)acetamides (6a-l) in DMF and lithium 
hydride as a base to afford various 2-{2,3-dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)sulfonyl]
amino}-N-(un/substituted-phenyl)acetamides (7a-l). All the synthesized compounds were characterized 
by their IR and 1H-NMR spectral data along with CHN analysis data. The enzyme inhibitory activities 
of these compounds were tested against a-glucosidase and acetylcholinesterase (AChE). Most of the 
compounds exhibited substantial inhibitory activity against yeast a-glucosidase and weak against AChE. 
The in silico molecular docking results were also consistent with in vitro enzyme inhibition data.
Keywords: Benzodioxane. Acetamide. Spectral analysis. α-Glucosidase. Acetylcholinesterase. Molecular 
docking.
INTRODUCTION
Sulfonamides are chemotherapeutic compounds 
consisting of a –SO2NH2 functional group that are of 
biological importance in the fight against pathogenic 
microbes and they have brought on a revolution in the field 
of pharmaceutical chemistry. Pathogenic microbes are a 
great threat to human health and are a cause of growing 
concern among people across the world. These compounds 
were firstly used as antibacterial agents (Reddy et al., 
2012; Alsughayer et al., 2011; Mahdi et al., 2015). Many 
sulfa drugs are widely used against various diseases as 
antifungal (Rathod et al., 2012), antimicrobial (Ajeet, 
Kumar, 2014), antitumor agents (Huang, Lin Huang, 
2001) and antihypertensive (Bhagwat et al., 2014) agents. 
Sulfonamides act as antiviral and antitumor agents and they 
are used to inhibit cancer cell growth and to block tumor 
invasion (Huang, Lin, Huang, 2001; Ghorab et al., 2016). 
Some sulfonamides act as good anti-proliferative agents 
and show promising broad-spectrum antitumor activity 
as compared to that of the commonly used anticancer 
drugs (Kasimogullari et al., 2015). Many sulfonamide 
derivatives are effective inhibitors of butyrylcholinesterase 
(BChE), acetylcholinesterase (AChE) for the treatment of 
Alzheimer’s disease (AD) (Abbasi et al., 2014a) and also 
show a good inhibitory potential against α-glucosidase 
and lipoxygenase (Abbasi et al., 2014b).
The compounds that have a 1,4-benzodioxane 
moiety exhibit a wide range of attractive biological 
activities, and their synthesis has received considerable 
attention over the years. Compounds with this moiety have 
biological activities such as anti-hepatotoxic (Ahmad, iD
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Khan, Alam, 2003), α-adrenergic blocking (Chapleo 
et al., 1983) and anti-inflammatory (Vazquez, Rosell, 
Pujol, 1997). The 1,4-benzodioxane ring system is also 
a part of many pharmaceutically important compounds 
such as silybin, americanin A6 and haedoxan A7, which 
show anti-hepatotoxic and insecticidal activities (Irshad 
et al., 2014). Flavonolignans were first discovered in the 
seeds of Silybum marianum, commonly known as milk 
thistle. The original flavonolignan to be discovered was 
silybin, and it is still the most studied flavonolignan and 
1,4-benzodioxane lignin (Abouzid, Ahmad, 2013; Pelter, 
Hansel, 1968). Silybin has shown a range of different 
biological activities including hepatoprotective, anticancer 
and antioxidant, among others (Kren, Walterova, 2005; 
Gazak, Walterova, Kren, 2007; Kaspaday et al., 2009).
a-Glucosidase (EC 3.2.1.20) belongs to the 
family of hydrolases and is located in the brush border 
surface membrane of small intestinal cells (Chiba, 
1997). a-Glucosidase inhibitors are used as oral anti-
diabetic drugs for patients with type-2 diabetes mellitus 
(T2DM). Postprandial hyperglycemia plays a vital 
role in the development of T2DM and nephropathy, 
neuropathy, microangiopathy, macroangiopathy 
which are complications associated with this disease 
(Lebovitz, 1997). The inhibitors of this enzyme can 
delay the release of D-glucose from oligosaccharides and 
disaccharides from dietary complex carbohydrates and 
delay glucose absorption, resulting in reduced postprandial 
hyperglycemia. Hence, the inhibition of a-glucosidase is 
an important step in the treatment of T2DM (Chapdelaine, 
Trembley, Dube, 1978; Abbasi et al., 2016). Several 
marketed drugs including acarbose and voglobiose are 
famous inhibitors of a-glucosidase.
Cholinesterases such as AChE (EC 3.1.1.7) and BChE 
(EC 3.1.1.8) belong to the serine hydrolase class. These are 
the best potential targets for the symptomatic treatment of AD 
and its related disorders. The specificities of the enzymes for 
their substrates and inhibitors depend on differences in the 
amino acid residues of the active sites of the two esterases. 
AChE catalyzes the hydrolysis of the neurotransmitter 
acetylcholine, terminating the nerve impulse at 
cholinergic synapses (Tougu, 2001; Gautheir, 2001). 
The revolutionary importance of sulfonamides in 
the field of pharmacology encouraged us to synthesize 
new sulfonamide-acetamide der ivat ives  us ing 
1,4-benzodioxane as central moiety. In the present work, 
a number of N-substituted derivatives starting from 
2,3-dihydro-1,4-benzodioxin-6-amine were synthesized. 
The first, parent sulfonamide N-(2,3-dihydrobenzo[1,4]-
dioxin-6-yl)-4-methylbenzenesulfonamide (3) was 
prepared by reacting 2,3-dihydro-1,4-benzodioxin-6-
amine (1) with 4-methylbenzenesulfonyl chloride (2) by 
stirring in aqueous alkaline medium at room temperature, 
and it was then further derivatized with different 
2-bromo-N-(un/substituted-phenyl)acetamides (6a-l) to 
get targeted molecules (7a-l). These newly synthesized 
molecules were then screened against a-glucosidase and 
acetylcholinesterase enzymes to explore their therapeutic 
potential for T2DM and AD.
MATERIAL AND METHODS
General
The chemicals utilized were procured from Sigma 
Aldrich/Alfa Aesar. The solvents used in reactions were of 
analytical grade and used as such. Pre-coated TLC silica 
gel G-25-UV254 plates were used to monitor the reactions 
using various percentages of n-hexane and ethyl acetate as 
solvent system. Melting points of compounds were recorded 
using a Gallenkamp melting point apparatus with open 
capillary tube. A MIDAC M2000 photon spectrometer was 
used to record the FTIR spectra in KBr (υ, cm-1). A Burker 
spectrometer operating at 25 °C at 400/600 MHz was used 
to record the 1H NMR spectra in CDCl3. The coupling 
constant (J) is given in Hz and chemical shift (a) in ppm. The 
abbreviations used in the interpretation of 1H NMR spectra 
are as follows: s, singlet; d, doublet; dd, doublet of doublets; 
t, triplet; br.t, broad triplet; q, quartet; quin, quintet; sex, 
sextet; sep, septet; m, multiplet. 
Synthesis
Synthesis of N-(2,3-dihydrobenzo[1,4]-dioxin-6-yl)-4-
methylbenzenesulfonamide (3)
N-(2,3-Dihydrobenzo[1,4]-dioxin-6-amine (1mL; 
0.002 mol; 1) was suspended in 25 mL distilled water and 
stirred for half an hour. Next, 10% aqueous Na2CO3 was 
added to maintain the pH at 9-10, and the reaction mixture 
stirred for half an hour. 4-Methylbenzenesulfonyl chloride 
(0.47 g; 0.002 mol; 2) was then added to the mixture 
along with gradual stirring, which was further stirred for 
several hours until completion of the reaction, which was 
monitored by TLC until a single spot was obtained. The 
product was precipitated at pH 2 using conc. HCl and 
filtered out, washed with distilled water, and air-dried 
to afford N-(2,3-dihydrobenzo[1,4]-dioxin-6-yl)-4-
methylbenzenesulfonamide (3): a light brown amorphous 
powder; yield 80%; m.p. 129-130 °C; molecular formula: 
C15H15O4NS; molecular weight: 305.367 gmol-1; IR: 3248 
(N-H stretching), 3045 (C-H stretching of aromatic ring), 
2926 (-CH2 stretching), 1633 (C=C stretching of aromatic 
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ring), 1383 (-SO2 stretching); 1H-NMR: δ (ppm) 10.12 (s, 
1H, NHSO2), 7.57 (d, J = 7.8 Hz, 2H, H-2’ & H-6’), 7.27 
(d, J =7.8 Hz, 2H, H-3’ & H-5’), 6.62 (d, J = 8.4 Hz, 1H, 
H-8), 6.56 (d, J =2.4 Hz, 1H, H-5), 6.47 (dd, J = 2.4,8.4 
Hz, 1H, H-7), 4.15 (br.s, 4H, CH2-2, CH2-3), 2.43 (s, 3H, 
CH3-7’).
General procedure for the synthesis of 2-bromo-N-
(un/substituted-phenyl)acetamides (6a-l)
2-Bromo-N-(un/substituted-phenyl)acetamides 
(6a-l) were prepared by vigorous manual shaking of un/
substituted anilines (0.16 g; 0.55 mmol; 4a-l, one in each 
reaction) with bromoacetyl bromide (0.2 g; 0.50 mmol; 
5). The pH of the solution was maintained by using 10% 
aqueous Na2CO3. The completion of the reaction was 
monitored by TLC till single spot. Afterwards, the reaction 
mixture was poured on crushed ice. The precipitated 
products were filtered, washed and dried to acquire the 
pure products (6a-l).
General procedure for the synthesis of 2-{2,3-dihydro-
1,4-benzodioxin-6-yl[(4- methylphenyl)- sulfonyl]
amino}-N-(un/substituted-phenyl)acetamides (7a-l)
N-(2,3-Dihydrobenzo[1,4]-dioxin-6-yl)-4-
methylbenzenesulfonamide (0.2 g; 0.57 mmol; 3) in 10 
mL N,N-dimethyl formamide (DMF) was placed into a 
50-mL round-bottomed flask along with lithium hydride 
(0.004 g) and the reaction mixture was stirred for 30 min 
at 25 °C. 2- Bromo-N-(un/substituted-phenyl)acetamides 
(0.60 mmol; 6a-l) were added to the reaction mixture, 
which was further stirred for 3-4 h. The reaction was 
monitored by TLC until a single spot. After completion, 
the reaction mixture was poured onto crushed ice and 
precipitated products were filtered out, washed and air 
dried to obtain the pure products (7a-l).
Spectral characterization
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-phenylacetamide (7a)
Light pink amorphous powder; yield 82%; mp 
177-178 °C; molecular formula C23H22O5N2S; molecular 
weight 438 g mol-1; IR (KBr) υ (cm -1): 3249 (N-H 
stretching), 3047 (C-H stretching of aromatic ring), 2929 
(-CH2 stretching), 1715 (C=O stretching), 1635 (C=C 
stretching of aromatic ring), 1387 (-SO2 stretching); 
1H-NMR: a (ppm) 8.31 (s, 1H, NHCO), 7.64 (d, J = 8.0 Hz, 
2H, H-2’ & H-6’), 7.52 (m, 2H, H-2’’’ & H-6’’’), 7.33-7.28 
(m, 4H, H-3’, H-5’, H-3’’’ & H-5’’’), 7.11 (br.t, J = 7.2 Hz, 
1H, H-4’’’), 6.75 (d, J = 8.4 Hz, 1H, H-8), 6.66 (d, J = 2.4 
Hz, 1H, H-5), 6.53 (dd, J =2.4, 8.4 Hz, 1H, H-7), 4.22-4.21 
(m, 4H, CH2-2 & CH2-3), 4.19 (br.s, 2H, CH2-2’’), 2.43 
(s, 3H, CH3-7’). Anal. Calc. for C23H22O5N2S (438.12): C, 
63.00; H, 5.06; N, 6.39. Found: C, 63.31; H, 5.19; N, 6.53.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(2-methoxyphenyl)- acetamide (7b)
Amorphous powder; yield 78%; m.p. 119-120 °C; 
molecular formula C24H24O6N2S; molecular weight 
468 g mol-1. IR (KBr) υ (cm-1): 3247 (N-H stretching), 
3049 (C-H stretching of aromatic ring), 2930 (-CH2 
stretching), 1713 (C=O stretching), 1637 (C=C stretching 
of aromatic ring), 1383 (-SO2 stretching); 1H-NMR: 
a (ppm) 8.23 (s, 1H, NHCO), 7.57 (d, J = 7.8 Hz, 2H, H-2’ 
& H-6’), 7.27 (d, J = 7.8 Hz, 2H, H-3’ & H-5’), 6.96 (m, 
2H, H-3’’’ & H-5’’’), 6.70 (br.t, J = 7.2 Hz, 1H, H-4’’’), 
6.62 (d, J = 8.4 Hz, 1H, H-8), 6.56 (d, J = 2.4 Hz, 1H, H-5), 
6.47 (dd, J = 2.4,8.4 Hz, 1H, H-7), 6.14 (br.d, J = 8.5, 1H, 
H-6’’’), 4.25 (br.s, 2H, CH2-2’’), 4.15 (br.s, 4H, CH2-2 & 
CH2-3), 3.87 (s, 3H, 2-OCH3), 2.40 (s, 3H, CH3-7’). Anal. 
Calc. for C15H15O4NS (468.14): C, 61.52; H, 5.16; N, 5.98. 
Found: C, 61.74; H, 5.27; N, 6.19.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(4-ethoxyphenyl)-acetamide (7c) 
Pinkish amorphous powder; yield 80%; m.p. 156-
157 °C; molecular formula C25H26N2O6S; molecular weight 
482 gmol-1; IR (KBr) υ (cm-1): 3251 (N-H stretching), 3047 
(C-H stretching of aromatic ring), 2927 (-CH2 stretching), 
1717 (C=O stretching), 1635 (C=C stretching of aromatic 
ring), 1387 (-SO2 stretching); 1H NMR: a (ppm) 8.25 (s, 
1H, NHCO), 7.55 (d, J = 8.4 Hz, 2H, H-2’ & H-6’), 7.35 
(d, J = 8.4 Hz, 2H, H-3’ & H-5’), 7.32 (d, J = 9.0 Hz, 2H, 
H-2’’’ & H-6’’’), 6.82 (d, J = 9.0 Hz, 2H, H-3’’’ & H-5’’’), 
6.72 (d, J = 2.4 Hz, 1H, H-5), 6.70 (d, J = 8.4 Hz, 1H, H-8), 
6.58 (dd, J = 2.4, 8.4 Hz, 1H, H-7), 4.32 (br.s, 2H, CH2-2’’), 
4.20-4.18 (m, 4H, CH2-2 & CH2-3), 3.98 (q, J = 7.2 Hz, 2H, 
4-OCH2CH3), 2.43 (s, 3H, CH3-7’), 1.34 (t, J = 7.2 Hz, 3H, 
4-OCH2CH3). Anal. Calc. for C25H26O6N2S (482.15): C, 
62.23; H, 5.43; N, 5.81. Found: C, 62.41; H, 5.57; N, 5.93.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(2-methylphenyl)- acetamide (7d)
Dark brown amorphous powder; yield 80%; m.p. 
95-96 °C; molecular formula C24H24N2O5S; molecular 
weight 452 gmol-1; IR (KBr) υ (cm-1): 3257 (N-H stretching), 
3043 (C-H stretching of aromatic ring), 2930 (-CH2 
stretching), 1719 (C=O stretching), 1640 (C=C stretching 
of aromatic ring), 1389 (-SO2 stretching); 1H-NMR: a (ppm) 
8.13 (s, 1H, NHCO), 7.54 (d, J = 8.5 Hz, 2H, H-2’ & H-6’), 
7.36 (d, J = 8.5 Hz, 2H, H-3’ & H-5’), 7.27 (br.d, J = 7.0 Hz, 
1H, H-6’’’), 7.18 (br.d, J = 7.5 Hz, 1H, H-3’’’), 7.15-7.13 (m, 
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1H, H-5’’’), 7.12-7.10 (m, 1H, H-4’’’), 6.75 (br.s, 1H, H-5), 
6.73 (d, J = 6.5 Hz, 1H, H-8), 6.60 (dd, J = 2.5-8.5 Hz, 1H, 
H-7), 4.34 (br.s, 2H, CH2-2’’), 4.22-4.19 (m, 4H, CH2-2 & 
CH2-3), 2.43 (s, 3H, CH3-7’), 2.08 (s, 3H, CH3-2’’’). Anal. 
Calc. for C24H24N2O5S (452.14): C, 63.70; H, 5.35; N, 6.19. 
Found: C, 63.83; H, 5.44; N, 6.31.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(3-methylphenyl)- acetamide (7e) 
Amorphous powder; yield 80%; m.p. 114-115 °C; 
molecular formula C24H24N2O5S; molecular weight 452 
gmol-1: IR (KBr) υ (cm-1): 3251 (N-H stretching), 3045 
(C-H stretching of aromatic ring), 2933 (-CH2 stretching), 
1717 (C=O stretching), 1641 (C=C stretching of aromatic 
ring), 1390 (-SO2 stretching); 1H-NMR: a (ppm) 8.19 (s, 
1H, NHCO), 7.55 (d, J = 8.4 Hz, 2H, H-2’ & H-6’), 7.35 
(d, J = 8.4 Hz, 2H, H-3’ & H-5’), 7.30 (br.s, 1H, H-2’’’), 
7.26 (br.d, J = 7.8 Hz, 1H, H-6’’’), 7.15 (br.d, J = 7.8 Hz, 
1H, H-5’’’), 6.91 (br.d, J = 7.2 Hz, 1H, H-4’’’), 6.71 (d, 
J = 9.0 Hz, 1H, H-8), 6.56 (d, J = 2.4 Hz, 1H, H-5), 6.47 (dd, 
J = 2.4,8.4 Hz, 1H, H-7), 4.34 (br.s, 2H, CH2-2’’), 4.20-4.18 
(m, 4H, CH2-2 & CH2-3), 2.29 (s, 3H, CH3-3’’’), 2.43 (s, 3H, 
CH3-7’). Anal. Calc. for C24H24N2O5S (452.14): C, 63.70; H, 
5.35; N, 6.19. Found: C, 63.88; H, 5.41; N, 6.27.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(4-methylphenyl)- acetamide (7f)
Of white amorphous powder; yield 80%; m.p. 134-
135 °C; molecular formula C24H24O5N2S; molecular weight 
452 gmol-1; IR (KBr) υ (cm-1): 3258 (N-H stretching), 3047 
(C-H stretching of aromatic ring), 2936 (-CH2 stretching), 
1711 (C=O stretching), 1643 (C=C stretching of aromatic 
ring), 1385 (-SO2 stretching); 1H-NMR: a (ppm) 8.29 (s, 
1H, NHCO), 7.51 (d, J = 8.0 Hz, 2H, H-2’ & H-6’), 7.36 (d, 
J = 8.5 Hz, 2H, H-3’ & H-5’), 7.28 (d, J = 8.0, 2H, H-2’’’ & 
H-6’’’), 7.11 (d, J = 8.0 Hz, 2H, H-3’’’ & H-5’’’), 6.75 (d, 
J = 8.5 Hz, 1H, H-8), 6.66 (d, J = 2.5 Hz, 1H, H-5), 6.53 
(dd, J = 2.5,8.5 Hz, 1H, H-7), 4.22-4.19 (m, 4H, CH2-2 & 
CH2 -3), 4.18 (br.s, 2H, CH2-2’’), 2.43 (s, 3H, CH3-7’), 2.29 
(s, 3H, CH3-4’’’). Anal. Calc. for C24H24N2O5S (452.14): C, 
63.70; H, 5.35; N, 6.19. Found: C, 63.81; H, 5.46; N, 6.23.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(2,3-dimethylphenyl)- acetamide (7g)
Of whi te  amorphous  powder ;  y ie ld  80%; 
mp 84-85 °C; molecular formula C25H26N2O5S; molecular 
weight 466 gmol-1; IR (KBr) υ (cm -1): 3261 (N-H 
stretching), 3053 (C-H stretching of aromatic ring), 2940 
(-CH2 stretching), 1718 (C=O stretching), 1647 (C=C 
stretching of aromatic ring), 1389 (-SO2 stretching); 
1H-NMR: a (ppm) 8.25 (s, 1H, NHCO), 7.64 (br.t, 
J = 7.8 Hz, H-5’’’), 7.50 (d, J = 8.4 Hz, 2H, H-2’ & H-6’), 
7.28 (d, J = 8.0 Hz, 2H, H-3’ & H-5’), 6.98-6.96 (m, 2H, 
H-4’’’ & H-6’’’), 6.76 (d, J = 8.4 Hz, 1H, H-8), 6.67 (d, 
J = 2.4 Hz, 1H, H-5), 6.53 (dd, J = 2.4,8.4 Hz, 1H, H-7), 
4.22-4.21 (m, 6H, CH2-2, CH2-3 & CH2-2’’), 2.43 (s, 3H, 
CH3-7’), 2.26 (s, 3H, CH3-3’’’), 2.24 (s, 3H, CH3-2’’’). 
Anal. Calc. for C25H26N2O5S (466.16): C, 64.36; H, 5.62; 
N, 6.00. Found: C, 64.44; H, 5.71; N, 6.19.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(2,4-dimethylphenyl)- acetamide (7h) 
Light pink amorphous powder; yield 80%; m.p. 150-
151 °C; molecular formula C25H26N2O5S; molecular weight 
466 gmol-1; IR (KBr) υ (cm-1): 3265 (N-H stretching), 3055 
(C-H stretching of aromatic ring), 2937 (-CH2 stretching), 
1721 (C=O stretching), 1649 (C=C stretching of aromatic 
ring), 1383 (-SO2 stretching); 1H-NMR: a (ppm) 8.27 (s, 
1H, NHCO), 7.48 (d, J = 8.4 Hz, 2H, H-2’ & H-6’), 7.26 (d, 
J = 8.4 Hz, 2H, H-3’ & H-5’), 6.78 (d, J = 8.4 Hz, 1H, H-8), 
6.73 (s, 1H, H-3’’’), 6.69 (d, J = 2.4 Hz, 1H, H-5),6.58 (d, 
2H, H-5’’’ & H-6’’’), 6.55 (dd, J = 2.4, 8.4 Hz, 1H, H-7), 
4.22-4.21 (m, 6H, CH2-2, CH2-3 & CH2-2’’), 2.43 (s, 3H, 
CH3-7’), 2.29 (s, 3H, CH3-4’’’), 2.23 (s, 3H, CH3-2’’’). 
Anal. Calc. for C25H26N2O5S (466.16): C, 64.36; H, 5.62; 
N, 6.00. Found: C, 64.49; H, 5.68; N, 6.23.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(2,5-dimethylphenyl)- acetamide (7i)
Light purple amorphous powder; yield 80%; m.p. 
115-116 °C; molecular formula C25H26N2O5S; molecular 
weight 466 gmol-1; IR (KBr) υ (cm -1): 3255 (N-H 
stretching), 3057 (C-H stretching of aromatic ring), 2937 
(-CH2 stretching), 1721 (C=O stretching), 1650 (C=C 
stretching of aromatic ring), 1391 (-SO2 stretching); 1H 
NMR: a (ppm) 8.31 (s, 1H, NHCO), 7.51 (d, J = 8.4 Hz, 
2H, H-2’ & H-6’), 7.28 (d, J = 8.4 Hz, 2H, H-3’ & H-5’), 
6.76 (d, J = 8.4 Hz, 1H, H-8), 6.68 (d, J = 2.4 Hz, 1H, 
H-5), 6.54 (dd, J = 2.4, 8.4 Hz, 1H, H-7), 4.23-4.22 (m, 
6H, CH2-2, CH2-3 & CH2-2’’), 2.43 (s, 3H, CH3-7’), 2.28 
(s, 3H, CH3-5’’’), 2.16 (s, 3H, CH3-2’’’). Anal. Calc. for 
C25H26N2O5S (466.16): C, 64.36; H, 5.62; N, 6.00. Found: 
C, 64.47; H, 5.77; N, 6.22.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(2,6-dimethylphenyl)- acetamide (7j) 
Amorphous powder; yield 80%; m.p. 86-87 °C; 
molecular formula C25H26N2O5S; molecular weight 466 
gmol-1; IR (KBr) υ (cm-1): 3253 (N-H stretching), 3055 
(C-H stretching of aromatic ring), 2939 (-CH2 stretching), 
1719 (C=O stretching), 1647 (C=C stretching of aromatic 
ring), 1388 (-SO2 stretching); 1H NMR: a (ppm) 7.93 (s, 
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1H, NHCO), 7.50 (d, J = 8.5 Hz, 2H, H-2’ & H-6’), 7.28 
(d, J = 8.0 Hz, 2H, H-3’ & H-5’), 7.08 (br.t, J = 7.5 Hz, 1H, 
H-4’’’), 6.78 (d, J = 8.5 Hz, 1H, H-8), 6.70 (d, J = 2.5 Hz, 
1H, H-5), 6.57 (dd, J = 2.5,8.5 Hz, 1H, H-7), 4.27 (br.s, 2H, 
CH2-2’’), 4.25-4.22 (m, 4H, CH2-2 & CH2-3), 2.43 (s, 3H, 
CH3-7’), 2.09 (s, 6H, CH3-2’’’ & CH3-6’’’). Anal. Calc. for 
C25H26N2O5S (466.16): C, 64.36; H, 5.62; N, 6.00. Found: 
C, 64.46; H, 5.75; N, 6.24.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(3,4-dimethylphenyl)- acetamide (7k). 
Light pink amorphous powder; yield 80%; mp 159-
160 °C; molecular formula C25H26O5N2S; molecular weight 
466 gmol-1; IR (KBr) υ (cm-1): 3257 (N-H stretching), 3050 
(C-H stretching of aromatic ring), 2937 (-CH2 stretching), 
1713 (C=O stretching), 1645 (C=C stretching of aromatic 
ring), 1389 (-SO2 stretching); 1H-NMR: a (ppm) 8.23 (s, 
1H, NHCO), 7.51 (d, J = 8.0 Hz, 2H, H-2’ & H-6’), 7.28 
(d, J = 8.4 Hz, 2H, H-3’ & H-5’), 7.24 (merged in the signal 
of CDCl3, 2H, H-2’’’ & H-6’’’), 7.05 (br.d, J = 8.0 Hz, 1H, 
H-5’’’), 6.75 (d, J = 8.8 Hz, 1H, H-8), 6.65 (d, J = 2.4 Hz, 
1H, H-5), 6.53 (dd, J = 2.8, 8.4 Hz, 1H, H-7), 4.23-4.19 
(m, 4H, CH2-2, CH2-3), 4.18 (br.s, 2H, CH2-2’’), 2.43 (s, 
3H, CH3-7’), 2.23 (s, 3H, CH3-3’’’), 2.20 (s, 3H, CH3-4’’’). 
Anal. Calc. for C25H26N2O5S (466.16): C, 64.36; H, 5.62; 
N, 6.00. Found: C, 64.39; H, 5.76; N, 6.12.
2-{2,3-Dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(3,5-dimethylphenyl)- acetamide (7l). 
Light pink amorphous powder; yield 80%; mp 130-
131 °C; molecular formula C25H26N2O5S; molecular weight 
466 gmol-1; IR (KBr) υ (cm-1): 3260 (N-H stretching), 3058 
(C-H stretching of aromatic ring), 2935 (-CH2 stretching), 
1715 (C=O stretching), 1648 (C=C stretching of aromatic 
ring), 1390 (-SO2 stretching); 1H-NMR: a (ppm) 8.24 (s, 
1H, NHCO), 7.51 (d, J = 8.0 Hz, 2H, H-2’ & H-6’), 7.28 
(d, J = 8.0 Hz, 2H, H-3’ & H-5’), 7.12 (br.s, 2H, H-2’’’ & 
H-6’’’), 6.76-6.74 (m, 2H, H-8, H-4’’’), 6.66 (d, J = 2.4 Hz, 
1H, H-5), 6.53 (dd, J = 2.4,8.4 Hz, 1H, H-7), 4.22-4.21 (m, 
4H, CH2-2 & CH2-3), 4.17 (br.s, 2H, CH2-2’’), 2.43 (s, 3H, 
CH3-7’), 2.28 (s, 6H, CH3-3’’’ & CH3-5’’’). Anal. Calc. for 
C25H26N2O5S (466.16): C, 64.36; H, 5.62; N, 6.00. Found: 
C, 64.41; H, 5.73; N, 6.14.
Enzyme inhibition assays
α-Glucosidase assay
The enzyme inhibition activity against α-glucosidase 
was performed according to a reported method 
(Chapdelaine, Trembley, Dube, 1978). The enzyme 
assay was optimized for the given time at temperature to 
maintain the linearity of the enzyme reaction wherein the 
concentration of the substrate was not limiting (data not 
shown). The reaction mix consisted of phosphate buffer 
(50 mM, pH 6.8, 70 µL), test compound (0.5 mM, 10 
µL) and 10 µL (0.057 U) of enzyme, (Sigma Inc., Cat 
No. G5003, Type-I from Saccharomyces cerevisiae) to 
make a total volume of 100 µL, which was mixed well 
and pre-incubated for 10 min at 37 ºC and pre-read at 
400 nm. Next, 10 µL of 0.5 mM substrate, p-nitrophenyl-
D-glucopyranoside, was added to start the reaction, 
and incubation continued for another 30 min, followed 
by reading at 400 nm with a microplate reader (Epoch, 
BioTek, USA). The change in absorbance was used as 
an index for the measurement of percentage inhibition. 
Acarbose was used as the positive control. All the 
experiments were performed in triplicates. Inhibition (%) 
was calculated by the following equation:
EZ-Fit Enzyme Kinetics Software (Perrella Scientific 
Inc. Amherst, USA) was used to calculate IC50 values of 
the compounds. Active compounds were serially diluted 
to suitable concentrations of 0.25, 0.125, 0.0625, 0.03125, 
0.0156 mM and their percentage inhibition was determined, 
and the data were used for the calculations of IC50 values. 
Acetylcholinesterase assay
The enzyme inhibition assay against AChE was 
performed according to a reported method (Ellman et al., 
1961). The reaction mixture was prepared with 50 mM 
Na2HPO4 buffer (pH 7.7, 60 µL), test compound (0.5 
mM, 10 µL well-1), followed by the addition 10 µL of 
0.005 U Electrophorus electricus AChE (Sigma Inc.) 
to make a total volume of 100 µL. The contents were 
mixed, pre-incubated for 10 minutes at 37ºC, and pre-
read at 405 nm. Next, 10 µL of 0.5 mM the substrate 
acetylthiocholine iodide and 10 µL of 0.5 mM DTNB 
were added and reaction was started. The reaction contents 
were incubated for 15 minutes at 37ºC and absorbance 
was measured at 405 nm. These experiments were carried 
out in triplicate. Eserine (0.5 mM well-1) was employed 
as a positive control. The percentage inhibition and IC50 
values were calculated by the same method as described 
for α-glucosidase assay. 
Molecular docking
To predict the bioactive conformations, various 
ligands were docked into the binding pockets of the 
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enzymes by using the default parameters of MOE-Dock 
program. 
Ligand preparation
The three-dimensional (3D) structures of the 
synthesized compounds were made by using ChemDraw 
Ultra 12.0 (Cambridge Soft, 2001) and saved in MDL 
Mol file format which were then opened in Molecular 
Operating Environment (MOE 2009-2010). The energies 
of the compounds were minimized by using the default 
parameter of MOE energy minimization algorithm 
(gradients: 0.05, force field: MMFF94X). A database was 
created in which all the compounds were saved in the mdb 
file format for the next step of docking.
Receptor protein preparation
The 3D structures of receptor protein molecules of 
yeast α-glucosidase (PDB Code: 3NO4) and AChE (PDB 
Code: 1GQR) were retrieved from Protein Data Bank (Tan 
et al., 2010; Bar-on et al., 2002). All water molecules were 
released from the receptor proteins and 3D protonation 
was carried out by using Protonate 3D Option (Tan et al., 
2010; Bar-on et al., 2002). Protein molecules were energy 
minimized by using the default parameters of MOE 2009-
10 energy minimization algorithm (gradient: 0.05, Force 
Field: MMFF94X). By using default parameters of MOE-
Dock Program, all compounds were docked into binding 
pockets of the above proteins. The re-docking procedure 
was also used to increase the validity of docking protocol 
(Boström, Greenwood, Gottfries, 2003). 
Statistical analysis
All the experiments were carried out in triplicate. 
Statistical analysis was performed using Microsoft 
Excel 2010 and the results are provided as mean ± 
SEM.
RESULTS AND DISCUSSION
Chemistry
The designed 2-{2,3-dihydro-1,4-benzodioxin-6-
yl[(4-methylphenyl)sulfonyl]amino}-N-(un/substituted-
phenyl)acetamides (7a-l) were synthesized according to 
scheme 1 and Table I. The procedures and conditions of 
the reactions are discussed in the experimental section. For 
the synthesis of the target derivatives, the first step of the 
reaction was carried between N-2,3-dihydrobenzo[1,4]-
dioxin-6-amine (1) and 4-methylbenzenesulfonyl chloride 
(2) in aqueous alkaline medium. The reaction mixture 
was stirred for 4-5 hours at room temperature yielding 
the parent N-(2,3-dihydrobenzo[1,4]-dioxin-6-yl)-4-
methylbenzenesulfonamide (3). The parent compound 
was obtained as a light brown amorphous powder in 
good yield by the acidification of the reaction mixture 
with concentrated HCl to adjust pH 2-3. In a parallel 
reaction, different amines (4a-l, Table I) were reacted, 
one by one, with bromoacetyl bromide (5) to obtain 
respective electrophiles, 2-bromo-N-(un/substituted-
phenyl)acetamides (6a-l). In the final step, parent, 3, was 
coupled with different electrophiles (6a-l), in polar aprotic 
solvent, i.e. DMF using LiH as a base to afford the targeted 
N-2-{2,3-dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)
sulfonyl]amino}-N-(un/substituted-phenyl)acetamides 
(7a-l). The structures of these molecules were deduced 
by their IR and 1H-NMR spectral data, and CHN analysis 
also supported the assignment. 
The structural analysis of one of the compounds is 
discussed hereby in detail as a representative molecule. 
The molecule, 7f, was obtained as an off-white amorphous 
powder with 88% yield, having a melting point of 
134-135 oC. The molecular formula (C24H24O5N2S) of 
this compound was predicted by counting the number 
of protons in its 1H-NMR spectrum, and it was also 
supported by its CHN analysis data. Various functional 
groups in this molecule were determined by its IR data. 
The absorption band at 3258 cm-1 was peculiar for N-H 
stretching (amide). The other bands were observed at 
3047 (C-H stretching of aromatic ring), 2936 (-CH2 
stretching), 1711 (C=O stretching), 1643 (C=C stretching 
of aromatic ring), and 1385 (-SO2 stretching). In its 1H 
NMR spectrum, a singlet in highly deshielded region 
at a 8.29 accounted for an acetamidic proton (-NHCO). 
The 4-methylbenzenesulfonyl moiety in this molecule 
was characterized by an A2B2 spin system in the aromatic 
region, represented by two ortho-coupled doublets at a 
7.51 (2H, H-2’ & H-6’) and a 7.36 (2H, H-3’ & H-5’) along 
with a methyl singlet in the aliphatic region at δ 2.43. 
Similarly, another A2B2 spin system was observed for the 
aromatic protons of 4-methylphenyl moiety substituted 
on nitrogen atom. This moiety was characterized by two 
ortho-coupled doublets at a 7.28 (2H, H-2’’’ & H-6’’’), and 
a 7.11 (2H, H-3’’’ & H-5’’’) along with a methyl signal at 
δ 2.29 as singlet. An AMX spin system for a 6-amino-
benzodioxane moiety in the molecule, was corroborated by 
an ortho-coupled doublet at δ 6.75 (1H, H-8, J = 8.5 Hz), a 
meta-coupled doublet at a 6.66 (1H, H-5, J = 2.5 Hz), and 
a reciprocal doublet of doublet at a 6.53 (1H, H-7, J = 2.5, 
8.5 Hz). A multiplet at a 4.22-4.19 with integration of four 
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protons was deduced for two symmetrical methylene 
groups (CH2-2 & CH2 -3) in 1,4-benzodioxane moiety. 
A very close lying broad singlet at a 4.18 was assignable 
to a methylene group (2H, CH2-2’’) of an acetamido 
unit attached by its carbon atom with the sulfonamidic 
nitrogen atom in the molecule. Thus, on the basis of the 
above cumulative spectral evidence, the structure of 7f 
was designated 2-{2,3-dihydro-1,4-benzodioxin-6-yl[(4-
methylphenyl)sulfonyl]amino}-N-(4-methylphenyl)
acetamide. Similarly, the structures of all other synthetic 
derivatives were characterized, and their spectral data is 
given in experimental section.
Enzyme inhibition, molecular docking (in silico) 
and SAR study
In search for new suitable therapeutic agents for the 
control of type 2 Diabetes mellitus and for the treatment 
of Alzheimer’s disease, these synthesized molecules, 
7a-l, were screened against α-glucosidase and AChE, 
respectively. In general, these compounds exhibited 
moderate to high inhibitory potential against a-glucosidase 
and weak inhibition against AChE, which was evident 
from there IC50 values as compared to the standard 
acarbose and serine, respectively (Table II). 
Compound 7h showed potent inhibition against 
a-glucosidase with an IC50 of 34.21 ± 0.12 µM, which was 
better than acarbose, which had an IC50 of 37.38 ± 0.12 µM. 
The enhanced inhibitory potential of this molecule against 
this enzyme might be attributed to the incorporation of a 
2,4-dimethylphenyl moiety in this molecule. Similarly, 
molecules 7g and 7k, with 2,3-dimethylphenyl and 
3,4-dimethylphenyl moieties, respectively, also showed 
excellent activity. The IC50 values of these molecules were 
47.23 ± 0.14 μM and 52.45 ± 0.14 μM, respectively. All 
molecules showed weak inhibitory profiles against AChE. 
Molecule 7g exhibited an IC50 of 213.47 ± 0.14 μM which 
was the lowest among the studied molecules. Its possibly 
weak inhibitory potential may be due to the amalgamation 
of 2,3-dimethylphenyl in the core sulfonamide bearing a 
benzodioxane entity.
The in silico molecular docking data of these 
molecules was also in agreement with their in vitro enzyme 
inhibition data. Molecular docking was performed with 
selected residues of the active pockets of the enzymes. It is 
shown (Figure 1; 2D & 3D) that compound 7h was deeply 
bound in the binding pocket of α-glucosidase by making 
two strong interactions. Asp420 created polar interaction 
SCHEME 1 - Outline for the synthesis of 2-{2,3-dihydro-1,4-benzodioxin-6-yl[(4-methylphenyl)sulfonyl]amino}-N-(un/
substituted-phenyl)acetamides (7a-l). Reagents & Conditions: (1) 2,3-dihydrobenzo[1,4]dioxin-6-amine (1)/aq. Na2CO3 soln./
pH 9-10/4-methylbenzenesulfonyl chloride (2)/stirring at RT for 3-4 hours. (2) Un/substituted anilines (4a-l)/aq. Na2CO3 
soln./pH 9-10/stirring/bromoacetyl bromide (5)/vigorous manual shaking. (3) N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-
methylbenzenesulfonamide(3)/DMF/LiH/stirring for half an hour/addition of un/substituted electrophiles, 4a-l, followed by stirring 
for 4-5 hours at room temperature.
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with the amino proton of the ligand giving a bond length 
of 1.97 Å while Lys422 made an acidic interaction with 
sulfonyl oxygen showing a bond distance of 2.30 Å. 
Similarly, molecule 7g also made four interactions. Arg440 
showed a couple of strong acidic interactions with both 
the sulfonyl oxygen with a bond length of 2.02 and 2.69 
Å. Lys422 also made two arene-cation interactions with 
bond distances of 3.25 and 4.31 Å as shown in 2-D and 3-D 
(Figure 2). Likewise, 7k showed two acidic interactions 
between Arg404 and both with the sulfonyl oxygen with 
bond distances of 1.85Å and 2.36Å (Figure 3; 2D & 3D).
The molecular docking of 7g into the active pocket 
of AChE indicated two polar interactions, i.e., one between 
Tyr121 and sulfonyl oxygen (bond length: 1.89Å) while 
the second with carbonyl oxygen (bond length: 2.64Å) as 
depicted (Figure 4; 2D & 3D). The strength of the bond 
was clear from the bond distances of ligand and amino acid 
residues of protein, i.e., the shorter the bond distance, the 
stronger the interaction, and vice versa.
CONCLUSIONS
The targeted 2-{2,3-dihydro-1,4-benzodioxin-6-
yl[(4-methylphenyl)sulfonyl]amino}-N-(un/substituted-
phenyl)acetamides (7a-l) were synthesized in good yields. 
Some of the molecules exhibited promising inhibition 
TABLE I - Different substituents (-R1 & -R2) in scheme 1
Compd. -R1 -R2 Compd. -R1 -R2
4a, 6a, 7a -H -H 4g, 6g, 7g 2-CH3 3-CH3
4b, 6b, 7b 2-OCH3 -H 4h, 6h, 7h 2-CH3 4-CH3
4c, 6c, 7c 4-OC2H5 -H 4i, 6i, 7i 2-CH3 5-CH3
4d, 6d, 7d 2-CH3 -H 4j, 6j, 7j 2-CH3 6-CH3
4e, 6e, 7e 3-CH3 -H 4k, 6k, 7k 3-CH3 4-CH3
4f, 6f, 7f 4-CH3 -H 4l, 6l, 7l 3-CH3 5-CH3
TABLE II - Percent inhibition at 0.5 mM and IC50 values for α-Glucosidase and AChE.
Compound
α-Glucosidase AChE
Inhibition (%) IC50 (μM) Inhibition (%) IC50 (μM)
7a 91.21 ± 0.18 127.32 ± 0.12 17.32 ± 0.14 -
7b 76.31 ± 0.23 245.12 ± 0.16 - -
7c 87.54 ± 0.17 132.21 ± 0.11 - -
7d 82.51 ± 0.24 252.12 ± 0.17 28.56 ± 0.13 -
7e 91.21 ± 0.21 74.49 ± 0.11 72.52 ± 0.18 374.63 ± 0.16
7f 86.42 ± 0.22 136.34 ± 0.14 86.58 ± 0.19 316.42 ± 0.12
7g 94.57 ± 0.21 47.23 ± 0.14 79.24 ± 0.19 213.47 ± 0.14
7h 95.78 ± 0.19 34.21 ± 0.12 51.26 ± 0.16 482.53 ± 0.11
7i 91.21 ± 0.18 85.41 ± 0.12 52.65 ± 0.15 471.25 ± 0.13
7j 93.76 ± 0.23 92.12 ± 0.15 57.43 ± 0.18 429.72 ± 0.12
7k 94.23 ± 0.17 52.45 ± 0.14 81.62 ± 0.19 352.26 ± 0.16
7l 87.74 ± 0.29 239.31 ± 0.18 82.53 ± 0.17 342.54 ± 0.14
Acarbose 92.23 ± 0.16 37.38 ± 0.12 - -
Eserine - - 91.27 ± 1.17 0.04 ± 0.0001
Note: IC50 values (concentration at which there is 50% enzyme inhibition) of compounds were calculated from the inhibition data 
obtained after performing assays at high dilutions of the compounds as given in the assay method, and data were analyzed using 
EZ–Fit enzyme kinetics software (Perrella Scientific Inc. Amherst, MA, USA). Data are given as mean of three values (mean ± 
SEM., n = 3).
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FIGURE 1 - Molecular docking of 7h against α-glucosidase.
FIGURE 2 - Molecular docking of 7g against yeast α-glucosidase.
FIGURE 3 - Molecular docking of 7k against yeast α-glucosidase.
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against α-glucosidase which was also supported by 
molecular docking studies. So, it was concluded that 
some of the molecules might be considered as suitable 
therapeutic agents for type 2 diabetes. 
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